Drugs

, Volume 34, Issue 5, pp 519–538 | Cite as

Encainide

A Review of its Pharmacological Properties and Therapeutic Efficacy
  • Rex N. Brogden
  • Peter A. Todd
Drug Evaluation

Summary

Synopsis

Encainide1 is an antiarrhythmic drug with class IC activity which has been used in the treatment of life-threatening ventricular arrhythmias, symptomatic ventricular arrhythmias and supraventricular arrhythmias. The antiarrhythmic activity is due to the parent drug and its two principal active metabolites, and in the extensive metabolising phenotype (90% of patients), metabolites are present in plasma at higher concentrations than encainide itself Encainide produces little haemodynamic change in patients with left ventricular dysfunction and thus has considerable therapeutic potential in view of its efficacy in patients with ventricular tachycardia, premature ventricular complexes and the Wolff-Parkinson-White syndrome. However, this potential is reduced by a tendency for encainide to aggravate arrhythmia in a proportion of patients. At present there is no reliable method of identifying patients at risk for this potentially serious side effect. The most common non-cardiac side effects are dizziness and blurred vision which seldom necessitate withdrawal of treatment.

Thus, encainide has proved effective in controlling ventricular tachyarrhythmias including those which have not been controlled by other antiarrhythmic drugs.

Pharmacodynamic Properties

In a variety of studies of isolated cardiac tissue, the predominant effect of encainide and its metabolites was a significant decrease in maximum upstroke velocity of cardiac action potential indicative of a reduction in peak inward sodium current during depolarisation. Of the active metabolites of encainide, O-demethylencainide (ODE) and 3-methoxy-O-demethylencainide (MODE), ODE has the greater efficacy. In intact animal models, single intravenous doses of encainide prolonged His-Purkinje conduction time (HV interval) and intraventricular conduction time (QRS duration), but not refractoriness. However, 45 minutes after infusion, refractory periods of atrium and ventricle were prolonged, suggesting accumulation of the active metabolites, which were found more active than the unchanged drug in slowing conduction. In humans, as in animals, the electrophysiological effects of encainide after oral administration, or at least 30 minutes after intravenous infusion, differ from those immediately following intravenous injection.

Encainide differs from conventional sodium channel antagonists, such as quinidine, procainamide and disopyramide, in that it affects the ventricular refractory period to a lesser extent, is devoid of anticholinergic effects, and influences accessory pathway characteristics in patients with Wolff-Parkinson-White syndrome.

Encainide demonstrated antiarrhythmic properties in a variety of animal models, which has been confirmed in patients with ventricular or supraventricular arrhythmias. Administration of ODE and MODE to animals has clearly demonstrated their antiarrhythmic activity, although such activity is also exhibited by encainide itself.

When administered orally at dosages required to control ventricular arrhythmias encainide generally had little effect on haemodynamic variables and did not influence left ventricular function in patients with mild to moderate congestive heart failure. Radionuclide ventriculograms revealed no significant changes in ejection fraction or double product during exercise or at rest following encainide at a mean dose of 75mg 4 times daily orally.

Pharmacokinetic Properties

The pharmacology of encainide is influenced by the formation of active metabolites and the effects of genetic polymorphism of the debrisoquine/sparteine type on the metabolism and disposition of the drug. Absorption is almost complete after oral administration and peak plasma concentrations of encainide are attained in 1.1 to 3 hours, whereas those of the metabolites occur at a mean of 1.4 (ODE) and 5.7 hours (MODE). Mean steady-state plasma concentrations of ODE and MODE are 3 to 5 times higher than those of encainide in extensive metabolisers (90% of the Caucasian population), although this ratio is roughly reversed in poor metabolisers. The lower systemic bioavailability in extensive metabolisers (mean 26 to 30%) than in poor metabolisers (mean 83 to 88%) indicates that there is extensive ‘first-pass’ extraction in the extensive metabolisers. Protein binding is similar in both phenotypes, however. The pattern of urinary excretion of encainide differs according to phenotype, with ODE accounting for about 20% of the total dose recovered in urine in 24 hours in extensive metabolisers and for 5% of the dose in poor metabolisers. The pattern of excretion of other metabolites also differs. Although the phenotypic differences in the metabolism of encainide are important to the pharmacokinetic profile, their clinical significance is less clear. In fact, suppression of arrhythmias in poor metabolisers may be expected at the same dosages that are effective in extensive metabolisers, since plasma concentrations of encainide in poor metabolisers reach high levels. The elimination half-life of encainide in extensive metabolisers is short (about 2 hours), whereas that of the metabolites is much longer (5 to 37 hours for ODE). Consequently the metabolites cumulate during repeated oral administration. In poor metabolisers, however, the half-life of encainide is prolonged on average to between 11 and 22 hours.

Although patients with liver disease exhibit decreased oral and systemic clearance and increased oral bioavailability of encainide no significant change in dosage is required, whereas in patients with impaired renal function, changes in oral clearance, systemic bioavailability, and steady-state volume of distribution of the active metabolites necessitate a reduction in dosage to about one-third that in patients with normal renal function.

Therapeutic Trials

The majority of patients treated with encainide have presented with arrhythmias that were not controlled by previous treatment with other antiarrhythmic drugs.

In a few comparative trials, the efficacy of encainide was at least equivalent to that of disopyramide and quinidine with respect to the proportion of patients who responded with a 75 to 80% or greater reduction in the frequency of premature ventricular complexes per hour. However, in these few studies encainide was superior to either disopyramide or quinidine in completely suppressing arrhythmias. Initial findings indicate that encainide remains effective during long term treatment, but these results in patients with ventricular ectopy require confirmation in double-blind trials comparing encainide with other antiarrhythmic drugs in larger numbers of patients.

Several studies in patients with heart disease and symptomatic ventricular tachycardia or ventricular fibrillation have found encainide 50 to 200mg daily to be effective in suppressing arrhythmias in about 50% of patients, nearly all of whom had not responded to treatment with other drugs. These results obtained during both short term and longer periods of oral administration are encouraging. However, the risk of aggravation of preexisting arrhythmias appears greatest in over patients presenting with cardiomyopathy and/or sustained ventricular tachycardia. Since these events cannot be reliably predicted, further investigation into methods of minimising aggravation is needed.

Encainide has also been effective in preventing recurrence of a variety of supraventricular arrhythmias, usually in over 60% of patients, including those with Wolff-Parkinson-White syndrome. Initial studies in children with medically refractory supraventricular tachycardia have also been promising, and if initial results are confirmed in comparative trials, encainide could become a treatment of choice in view of its minimal haemodynamic effects.

Side Effects

The most common non-cardiac side effects associated with usual therapeutic doses of encainide are blurred vision, dizziness (7 to 10%) with headache, nausea and taste perversion occurring in 2 to 3% of patients. Like other antiarrhythmic drugs, encainide has the potential to aggravate and provoke cardiac arrhythmias and in comprehensive analyses of patients treated to date the overall incidence of proarrhythmic events (new arrhythmias, increased frequency of pre-existing arrhythmia, conversion from non-sustained to sustained ventricular tachycardia, incessant arrhythmia) has been about 9 to 16%. Overall, the incidence of such events has decreased in studies initiated since 1983, compared with the incidence in earlier studies, when dosage regimens were modified. Encainide has seldom aggravated congestive heart failure and is generally well tolerated by the elderly.

Dosage and Administration

The recommended initial dosage in adults with ventricular arrhythmias is 25mg 3 times daily. The dose can be increased to 35mg 3 times daily after 3 to 5 days and then, if necessary, to 50mg 3 times daily. The usual maximum recommended dose is 200mg daily in 4 divided doses. In patients with life-threatening (malignant) arrhythmias, treatment should be initiated where cardiac monitoring and advanced life support systems are available. Dosage adjustment is required in patients with moderate to severely impaired renal function.

Keywords

Ventricular Tachycardia Ventricular Arrhythmia Antiarrhythmic Drug Disopyramide Extensive Metabolisers 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abdollah H, Brugada P, Green M, Wehr M, Wellens HJJ. Clinical efficacy and electrophysiologic effects of intravenous and oral encainide in patients with accessory atrioventricular pathways and supraventricular arrhythmias. American Journal of Cardiology 54: 544, 1984PubMedCrossRefGoogle Scholar
  2. Anderson JL, Stewart JR, Johnson TA, Lutz JR, Pitt B. Response to encainide of refractory ventricular tachycardia: clinical application of assays for parent drug and metabolites. Journal of Cardiovascular Pharmacology 4: 812, 1982PubMedCrossRefGoogle Scholar
  3. Antonaccio MJ, Verjee S. Dosing recommendations for encainide. American Journal of Cardiology 58: 114C, 1986PubMedCrossRefGoogle Scholar
  4. Arnsdorf MF, Schmidt GA, Sawicki GJ. Effects of encainide on the determinants of cardiac excitability in Sheep Purkinje fibers. J. Pharmacol. Exp. Therap. 232: 40, 1985Google Scholar
  5. Barbey JT, Thompson KA, Echt DS, Woosley RL, Roden DM. Plasma concentration — response relations and disposition of encainide metabolites in man. Abstract. Clinical Research 34: 394A, 1986Google Scholar
  6. Bergstrand RH, Wang T, Roden DM, Stone WJ, Wolfenden HT, et al. Encainide disposition in patients with renal failure. Clinical Pharmacology and Therapeutics 40: 64, 1986aPubMedCrossRefGoogle Scholar
  7. Bergstrand RH, Wang T, Roden DM, Avant GR, Sutton WW, et al. Encainide disposition in patients with chronic cirrhosis. Clinical Pharmacology and Therapeutics 40: 148, 1986bPubMedCrossRefGoogle Scholar
  8. Blair IA, Sweetman BJ, Mayol RF, La Budde JA. The polar urinary metabolites of encainide. Acta Pharmacologica et Toxicologica (Suppl. V): 12–86, 1986Google Scholar
  9. Brugada P, Abdullah H, Wellens HJJ. Suppression of incessant supraventricular tachycardia by intravenous and oral encainide. J. Am. Coll. Card. 4: 1255, 1984CrossRefGoogle Scholar
  10. Brugada P, Wellens HJJ. Long term follow up of incessant supraventricular tachycardia treated with oral encainide. In press, 1987Google Scholar
  11. Brutsaert DL. Effects of encainide on myocardial contractility of cat papillary muscle. European Journal of Pharmacology 76: 267–269, 1981PubMedCrossRefGoogle Scholar
  12. Byrne JE, Gomoll AW. The antiarrhythmic action of encainide versus ventricular arrhythmias in the conscious dog following coronary artery ligation. Canadian Journal of Physiology and Pharmacology 60: 369, 1982PubMedCrossRefGoogle Scholar
  13. Campbell RWF, Nicholson MR, Julian DG. Ventricular tachycardia — management with encainide. Abstract 25. European Heart Journal 2(Suppl. A): 185, 1981Google Scholar
  14. Campbell TJ. Resting and rate-dependent depression of maximum rate of depolarisation (Vmax) in guinea-pig ventricular action potentials by mexiletine, disopyramide, and encainide. Journal of Cardiovascular Pharmacology 5: 291, 1983PubMedCrossRefGoogle Scholar
  15. Capos NJ, Kates RE, Harrison DC. Increased incidence of heart block induced by combined encainide, encainide metabolites and verapamil in dogs. Abstract 1080. Circulation 68(Suppl. III): III–270, 1983Google Scholar
  16. Carey EL, Duff HJ, Roden DM, Primm RK, Wilkinson GR, et al. Encainide and its metabolites: comparative effects in man on ventricular arrhythmia and electrocardiographic intervals. Journal of Clinical Investigation 73: 539, 1984PubMedCrossRefGoogle Scholar
  17. Carmeliet E. Electrophysiological effects of encainide on isolated cardiac muscle and Purkinje fibers and the Lagendorff-perfused guinea-pig heart. Europ. J. Pharmacol. 61: 247, 1980CrossRefGoogle Scholar
  18. Caron JF, Libersa CC, Kher AR, Kacet S, Wanszelbaum H. Comparative study of encainide and disopyramide in chronic ventricular arrhythmias: a double-blind placebo-controlled crossover study. J. Am. Coll. Card. 5: 1457, 1985CrossRefGoogle Scholar
  19. Cassagneau B, Miquel JP, Puel J, Massbuau P, Bounhoure JP. Treatment of recurrent supraventricular tachycardia with moderate or low doses of oral encainide. Abstract 1434. Circulation 68 (4, pt 2): III–359, 1983Google Scholar
  20. Chesnie B, Podrid P, Lown B, Raeder E. Encainide for refractory ventricular tachyarrhythmia. American Journal of Cardiology 52: 495–500, 1983PubMedCrossRefGoogle Scholar
  21. Davy J-M, Dorian P, Kantelip J-P, Harrison DC, Kates RE. Qualitative and quantitative comparison of the cardiac effects of encainide and its three major metabolites in the dog. J. Pharmacol. Exp. Therap. 237: 907–911, 1986Google Scholar
  22. Dawson AK, Roden DM, Duff HJ, Woosley RL, Smith RF. Differential effects of O-demethyl encainide on induced and spontaneous arrhythmias in the conscious dog. American Journal of Cardiology 54: 654, 1984PubMedCrossRefGoogle Scholar
  23. Dayer P, Balant L, Fabre J. The genetic control of drug oxidation in the liver. International Journal of Clinical Pharmacology Research 3: 421, 1983PubMedGoogle Scholar
  24. Di Bianco R, Fletcher RD, Cohen AI, Gottdiener JS, Singh SN, et al. Treatment of frequent ventricular arrhythmia with encainide: Assessment using serial ambulatory electrocardiograms, intracardiac electrophysiologic studies, treadmill exercise tests and radionuclide cineangiographic studies. Circulation 65: 1134, 1982CrossRefGoogle Scholar
  25. Di Bianco R, Gottdiener JS, Fletcher RD, Singh S, Katz RJ, et al. Effects of encainide on left ventricular function: Assessment with treadmill exercise and radionuclide ventriculography. Abstract 691. Circulation 62(Suppl. III): 182, 1980Google Scholar
  26. Dresel PE. Effect of encainide and its two major metabolites on cardiac conduction. Journal of Pharmacology and Experimental Therapeutics 228: 180, 1984PubMedGoogle Scholar
  27. Duff HJ, Dawson AK, Carey EL, Roden DM, Oates JA, et al. The electrophysiologic actions of O-demethyl encainide: an active metabolite. Clinical Research 29: 270A, 1981Google Scholar
  28. Duff HJ, Roden DM, Carey EL, Wang T, Primm K, et al. Spectrum of antiarrhythmic response to encainide. American Journal of Cardiology 56: 887, 1985PubMedCrossRefGoogle Scholar
  29. Dumoulin P, Jaillon P, Kher A, Poirier J-M, Cheymol G, et al. Long term efficacy and safety of oral encainide in the treatment of chronic ventricular ectopic activity: relationship to plasma concentrations — a French multicentre trial. American Heart Journal 110: 575, 1985PubMedCrossRefGoogle Scholar
  30. Eichelbaum M. Polymorphic drug oxidation in humans. Federation Proceedings 43: 2298, 1984PubMedGoogle Scholar
  31. Elharrar V, Zipes DP. Effects of encainide and metabolites (MJ 14030 and MJ 9444) on canine cardiac Purkinje and ventricular fibers. Journal of Pharmacology and Experimental Therapeutics 220: 440, 1982PubMedGoogle Scholar
  32. Gibson JK, Somani P, Bassett AL. Electrophysiologic effects of encainide (MJ 9067) on canine Purkinje fibres. European Journal of Pharmacology 52: 161, 1978PubMedCrossRefGoogle Scholar
  33. Gomoll AW, Byrne JE, Antonaccio MJ. Electrophysiology, hemodynamic and arrhythmic efficacy model studies on encainide. American Journal of Cardiology 58: 10–17C, 1986CrossRefGoogle Scholar
  34. Harrison DC. Antiarrhythmic drug classification: new science and practical applications. Am. J. Card. 56: 185–187, 1985PubMedCrossRefGoogle Scholar
  35. Heger JJ, Rinkenberger RL, Nattel S, Jackman W, Prystowsky E, et al. Encainide therapy in patients with drug resistant ventricular tachycardia. Abstract. Clinical Research 27: 614A, 1979Google Scholar
  36. Horowitz LN. Encainide in lethal ventricular arrhythmias evaluated by electrophysiologic testing and decrease in symptoms. American Journal of Cardiology 58: 83C, 1986PubMedCrossRefGoogle Scholar
  37. Jackman WM, Zipes DP, Naccarelli GV, Rinkenberger RL, Heger JJ, et al. Electrophysiology of oral encainide. American Journal of Cardiology 49: 1270, 1982PubMedCrossRefGoogle Scholar
  38. Jaillon P, de la Rosa S, Griffin JC, Winkle RA, Harrison DC. Effects of encainide (MJ 9067) on the ventricular fibrillation threshold in anaesthetised dogs. Journal of Cardiovascular Pharmacology 2: 517, 1980PubMedCrossRefGoogle Scholar
  39. Kates RE, Harrison DC, Winkle RA. Metabolite cumulation during long term oral encainide administration. Clinical Pharmacology and Therapeutics 31: 427, 1982PubMedCrossRefGoogle Scholar
  40. Kerr MJ, Allen JD, Harron DWG, Shanks RG. The effects of encainide and its major metabolites, O-demethyl encainide and 3-methyl-O-demethyl encainide, on experimental cardiac arrhythmias in dogs. J. Card. Pharmacol. 7: 449, 1985CrossRefGoogle Scholar
  41. King BW, Man RYK. Electrophysiological effects of encainide (MJ 9067) on canine subendocardial Purkinje fibres surviving infarction. Journal of Cardiovascular Pharmacology 6: 547, 1984PubMedCrossRefGoogle Scholar
  42. Kuck K-H, Kunze K-P, Kuch B, Bleifeld W. Acute and chronic electrophysiological effects of encainide and clinical follow-up in patients with accessory pathways. European Heart Journal 55: 124, 1984aGoogle Scholar
  43. Kuck K-H, Kunze KP, Roewer N, Bleifeld W. Encainide in incessant supraventricular tachycardia. Abstract. European Heart Journal 55: 125, 1984bGoogle Scholar
  44. Kunze K-P, Kuck K-H, Schluter M, Bleifeld W. Effect of encainide and flecainide on chronic ectopic atrial tachycardia. Journal of the American College of Cardiology 7: 1121, 1986PubMedCrossRefGoogle Scholar
  45. Libersa CC, Lekieffre JP, Caron JF, Poirier JM, Pladys AM, et al. Electrophysiological effects of encainide and its metabolites in 11 patients. J. Card. Pharmacol. 7: 1077, 1985CrossRefGoogle Scholar
  46. Loss LE, Koffer H, Schrogie JJ. Efficacy and tolerance of encainide in the elderly. Abstract. Clinical Research 33 (Pt 1, No. 2): 206A, 1985Google Scholar
  47. Loss L, Mullen C, De Lisser O, Koffer H, Schrogie J. Clinical effects of oral encainide in malignant ventricular arrhythmia. Abstract of paper presented at 57th American Heart Association Scientific Sessions, May 14, 1984Google Scholar
  48. Markel ML, Prystowsky EN, Heger JJ, Miles WM, Fineberg N, et al. Encainide for treatment of supraventricular tachycardias associated with the Wolff-Parkinson-White syndrome. American Journal of Cardiology 58: 41C, 1986PubMedCrossRefGoogle Scholar
  49. Mason JW. Basic and clinical electrophysiology of encainide. American Journal of Cardiology 58: 18C, 1986PubMedCrossRefGoogle Scholar
  50. Mason JW, Peters FA. Antiarrhythmic efficacy of encainide in patients with refractory recurrent ventricular tachycardia. Circulation 63: 670, 1981PubMedCrossRefGoogle Scholar
  51. McAllister CB, Wolfenden HT, Aslanian WS, Woosley RL, Wilkinson GR. Oxidative metabolism of encainide: polymorphism, pharmacokinetics and clinical considerations. Xenobiotica 16: 483, 1986PubMedCrossRefGoogle Scholar
  52. Metcalfe JM, Daly KM, Atkinson L, Monaghan M, Jewitt DE. Dose related haemodynamic effects of intravenous encainide. Abstract. American Journal of Cardiology 47: 483, 1981CrossRefGoogle Scholar
  53. Morganroth J. Risk factors for the development of proarrhythmic events. American Journal of Cardiology 59: 32–37E, 1987CrossRefGoogle Scholar
  54. Morganroth J, Pool P, Miller R, Hsu P-H, Lee I, et al. Dose-response range of encainide for benign and potentially lethal ventricular arrhythmias. American Journal of Cardiology 57: 769, 1986bPubMedCrossRefGoogle Scholar
  55. Morganroth J, Somberg JC, Pool PE, Hsu P-H, Lee IK, et al. Comparative study of encainide and quinidine in the treatment of ventricular arrhythmias. Journal of the American College of Cardiology 7: 9, 1986aPubMedCrossRefGoogle Scholar
  56. Nicholson MR, Campbell RWF, Julian DG. Encainide in management of ventricular tachycardia. Abstract. Australian and New Zealand Journal of Medicine 12: 313, 1982CrossRefGoogle Scholar
  57. Podrid PJ. Can antiarrhythmic drugs cause arrhythmia? Journal of Clinical Pharmacology 24: 313, 1984PubMedGoogle Scholar
  58. Podrid PJ. Aggravation of ventricular arrhythmia. Drugs 29(Suppl. 4): 33, 1985PubMedCrossRefGoogle Scholar
  59. Podrid PJ, Lampert S, Graboys TB, Blatt CM, Lown B. Aggravation of arrhythmia by antiarrhythmic drugs — incidence and predictors. American Journal of Cardiology 59: 38–44E, 1987CrossRefGoogle Scholar
  60. Poser R, Lombardi F, Podrid P, Lown B. Aggravation of induced arrhythmias with antiarrhythmic drugs during electrophysiological testing. Abstract. Journal of the American College of Cardiology 1: 709, 1983Google Scholar
  61. Prystowsky EN, Klein GJ, Rinkenberger RL, Heger JJ, Naccarelli GV, et al. Clinical efficacy and electrophysiologic effects of encainide in patients with Wolff-Parkinson-White syndrome. Circulation 69: 278, 1984PubMedCrossRefGoogle Scholar
  62. Quart BD, Durkee J, Soyka L. Polymorphic encainide oxidation: what is the clinical significance? Acta Pharmacologica et Toxicologica (Suppl. V): 333, 1986b.Google Scholar
  63. Quart BD, Gallo DG, Sami MH, Wood AJJ. Drug interaction studies and encainide use in renal and hepatic impairment. American Journal of Cardiology 58: 104C, 1986aPubMedCrossRefGoogle Scholar
  64. Rahilly GT, Prystowsky EN, Zipes DP, Naccarelli GV, Jackman WM, et al. Clinical and electrophysiologic findings in patients with repetitive monomorphic ventricular tachycardia and otherwise normal electrocardiogram. American Journal of Cardiology 50: 459, 1982PubMedCrossRefGoogle Scholar
  65. Rinkenberger RL, Prystowsky EN, Jackman WM, Naccarelli GV, Heger JJ, et al. Drug conversion of nonsustained ventricular tachycardia to sustained ventricular tachycardia during serial electrophysiologic studies: identification of drugs that exacerbate tachycardia and potential mechanisms. American Heart Journal 103: 177, 1982PubMedCrossRefGoogle Scholar
  66. Ro JH, Gillon J, Kupersmith J. Electrophysiologic effects of encainide following acute coronary occlusion in dogs. Journal of Cardiovascular Pharmacology 3: 532, 1981PubMedCrossRefGoogle Scholar
  67. Roden DM, Dawson AK, Duff HJ, Woosley RL, Smith RF. Electrophysiology of O-demethyl encainide in a canine model of sustained ventricular tachycardia. Journal of Cardiovascular Pharmacology 6: 588, 1984PubMedCrossRefGoogle Scholar
  68. Roden DM, Duff HJ, Altenbern D, Woosley RL. Antiarrhythmic activity of the O-demethyl metabolite of encainide. Journal of Pharmacology and Experimental Therapeutics 221: 552, 1982PubMedGoogle Scholar
  69. Roden DM, Reele SB, Higgins SB, Mayol RF, Grammars RE, et al. Total suppression of ventricular arrhythmias by encainide: pharmacokinetic and electrophysiologic characteristics. New England Journal of Medicine 302: 877, 1980PubMedCrossRefGoogle Scholar
  70. Roden DM, Wood AJJ, Wilkinson GR, Woosley RL. Disposition kinetics of encainide and metabolites. American Journal of Cardiology 58: 4C, 1986PubMedCrossRefGoogle Scholar
  71. Sami MH. Encainide: Its acute intravenous and long term oral hemodynamic effects in man. Paper presented at the Encainide Symposium, Phoenix, Arizona, Jan, 1986Google Scholar
  72. Sami MH, Derbekyan VA, Lisbona R. Hemodynamic effects of encainide in patients with ventricular arrhythmia and poor ventricular function. Am. J. Card. 52: 507, 1983PubMedCrossRefGoogle Scholar
  73. Sami M, Harrison DC, Kraemer H, Houston N, Shimasaki C, et al. Antiarrhythmic efficacy of encainide and quinidine: Validation of a model for drug assessment. American Journal of Cardiology 48: 147, 1981PubMedCrossRefGoogle Scholar
  74. Sami M, Mason JW, Ott G, Harrison DC. Canine electrophysiology of encainide, a new antiarrhythmic drug. American Journal of Cardiology 43: 1149, 1979aPubMedCrossRefGoogle Scholar
  75. Sami M, Mason JW, Peters F, Harrison DC. Clinical electrophysiologic effects of encainide, a newly developed antiarrhythmic agent. American Journal of Cardiology 44: 526, 1979bPubMedCrossRefGoogle Scholar
  76. Samuelsson RG, Harrison DC. Electrophysiologic evaluation of encainide with use of monophasic action potential recording. American Journal of Cardiology 48: 871, 1981PubMedCrossRefGoogle Scholar
  77. Southworth WF, Davis SC, Ruffy R. Encainide in drug resistant ventricular ectopy. Abstract. Clinical Research 29: 700A, 1981Google Scholar
  78. Soyka LF. Safety of encainide for the treatment of ventricular arrhythmias. American Journal of Cardiology 58: 96C, 1986PubMedCrossRefGoogle Scholar
  79. Strasburger JF, Moak JP, Smith RT, McVey-Duncan P, Armstrong K, et al. Encainide for refractory supraventricular tachycardia in children. Am. J. Card. 58: 49C, 1986PubMedCrossRefGoogle Scholar
  80. Thale J, Klein H, Shanks RG, Bander F. Acute and long term antiarrhythmic efficacy of encainide in chronic atrial ectopy [translation]. Zeitschrift für Kardiologie 74: 220, 1985PubMedGoogle Scholar
  81. Tordjman T, Podrid PJ, Raeder E, Lown B. Safety and efficacy of encainide for malignant ventricular arrhythmias. American Journal of Cardiology 58: 87C, 1986PubMedCrossRefGoogle Scholar
  82. Tucker CR, Winkle RA, Peters FA, Harrison DC. Acute haemodynamic effects of intravenous encainide in patients with heart disease. American Heart Journal 104: 209, 1982PubMedCrossRefGoogle Scholar
  83. Vanhaleweyk G, Serruys PW, Hugenholtz PG. Haemodynamic effects of encainide, flecainide, lorcainide and tocainide. European Heart Journal 5(Suppl. B): 67, 1984PubMedGoogle Scholar
  84. Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. Journal of Clinical Pharmacology 24: 129, 1984PubMedGoogle Scholar
  85. Wang T, Roden DM, Wolfenden HT, Woosley RL, Wood AJJ, et al. Influence of genetic polymorphism on the metabolism and disposition of encainide in man. Journal of Pharmacology and Experimental Therapeutics 228: 605, 1984PubMedGoogle Scholar
  86. Wellens HJJ, Brugada P. Electrophysiology in assessing supraventricular arrhythmias: value of programmed stimulation in predicting and understanding efficacy of encainide. American Journal of Cardiology 58: 37C, 1986PubMedCrossRefGoogle Scholar
  87. Winkle RA, Peters F, Kates RE, Harrison DC. Possible contribution of encainide metabolites to the long term antiarrhythmic efficacy of encainide. Am. J. Card. 51: 1182, 1983PubMedCrossRefGoogle Scholar
  88. Winkle RA, Peters F, Kates RE, Tucker C, Harrison DC. Clinical pharmacology and antiarrhythmic efficacy of encainide in patients with chronic ventricular arrhythmias. Circulation 64: 290–296, 1981PubMedCrossRefGoogle Scholar
  89. Wong SS, Myerburg RJ, Ezrin AM, Gelband H, Bassett AL. Electrophysiologic effects of encainide on acutely ischaemic rabbit myocardial cells. Europ. J. Pharmacol. 80: 323, 1982CrossRefGoogle Scholar
  90. Woosley RL, Roden DM, Dai G, Wang T, Altenbern D, et al. Co-inheritance of the polymorphic metabolism of encainide and debrisoquine. Clin. Pharmacol. Therap. 39: 282, 1986CrossRefGoogle Scholar
  91. Woosley RL, Roden DM, Duff HJ, Oates JA. Selection of an antiarrhythmic drug for a sudden death prevention trial. American Heart Journal 103: 737, 1982PubMedCrossRefGoogle Scholar

Copyright information

© ADIS Press Limited 1987

Authors and Affiliations

  • Rex N. Brogden
    • 1
  • Peter A. Todd
    • 1
  1. 1.ADIS Drug Information ServicesMairangi Bay, Auckland 10New Zealand

Personalised recommendations